Company profile

Light Chain Bioscience - Novimmune SA

Privately held: no public share price (Privately held Swiss antibody company; rebranded from NovImmune SA after divesting EmaCo to Sobi in 2019. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.swissbiotech.org/listing/novimmune-to-rebrand-as-light-chain-bioscience-after-divesting-emaco-to-swedish-biopharmaceutical-sobi/]) · Switzerland

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
NI-1801
Phase 1
Mesothelin (MSLN) x CD47 (bispecific)Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.